MedTrace Logo

Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment

NCT04274101 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2023-03-01

No results posted yet for this study

Summary

Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission.

Pharmacological treatment is given to prevent development of cardiac and gastrointestinal sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They both has proven efficacy for acute face treatment, with different security profiles. There are not enough adequate studies comparing both drugs made in a large number of subjects. Investigators will study 900 patients treated with both drugs and compare security and efficacy in a retrospective cohort.

Conditions

  • Chagas Disease

Interventions

OTHER

Clinical Manifestations

Clinical manifestations in patients treated with Nifurtimox and Benznidazole

DIAGNOSTIC_TEST

Serologic response

Serologic response in patients treated with Nifurtimox and Benznidazole

DIAGNOSTIC_TEST

Direct method

Direct method tests in patients treated with Nifurtimox and Benznidazole

BEHAVIORAL

Adverse events

Adverse events in patients treated with Nifurtimox and Benznidazole

Sponsors & Collaborators

  • Hospital de Niños R. Gutierrez de Buenos Aires

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-08-01
Completion
2025-02-01

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274101 on ClinicalTrials.gov